{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:57:01Z","timestamp":1794023821846,"version":"4.8.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. Since the approval of ipilimumab in 2011, a total of nine ICIs have gained indications for various solid and hematologic malignancies. The expanding use of ICIs in oncology underscores the need for diagnosis and treatment expertise in immune related adverse events (irAE). Cutaneous toxicities are the earliest and most common irAE in this class of therapy. In addition to the more frequent reactions including vitiligo, lichenoid dermatitis, psoriasiform dermatitis, other less common skin toxicities including bullous dermatoses, neutrophilic dermatoses, and autoimmune dermato-rheumatologic diseases have been reported. Even though less than 3% of cutaneous irAEs (irCAEs) are classified as grade 3 or higher events, irCAEs can greatly impact quality of life. Appropriate management of irCAEs is critical to avoid unwarranted interruptions or discontinuation of lifesaving immunotherapy.<\/jats:p>","DOI":"10.3389\/falgy.2023.1147513","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T04:24:44Z","timestamp":1677731084000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Mucocutaneous adverse events to immune checkpoint inhibitors"],"prefix":"10.3389","volume":"4","author":[{"given":"Fiorinda","family":"Muhaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmavathi V.","family":"Karri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wylie","family":"Moody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.3390\/curroncol29040234","article-title":"Cutaneous adverse events associated with immune checkpoint inhibitors: a review article","volume":"29","author":"Chen","year":"2022","journal-title":"Curr Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/biom12081031","article-title":"Dostarlimab: a review","volume":"12","author":"Costa","year":"2022","journal-title":"Biomolecules"},{"key":"B3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","article-title":"Nivolumab plus relatlimab: first approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/15569527.2022.2034842","article-title":"Adverse cutaneous toxicities by PD-1\/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance","author":"Bhardwaj","year":"2022","journal-title":"Cutan Ocul Toxicol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ijwd.2021.10.005","article-title":"Dermatologic immune-related adverse events: the toxicity spectrum and recommendations for management","volume":"7","author":"Apalla","year":"2021","journal-title":"Int J Womens Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/bjd.19750","article-title":"Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors","volume":"185","author":"Gault","year":"2021","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1080\/09546634.2021.1898529","article-title":"Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses","volume":"33","author":"Le","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/cncr.34004","article-title":"Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: incidence, management, and clinical benefit","volume":"128","author":"Patel","year":"2022","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40257-022-00706-y","article-title":"Challenging dermatologic considerations associated with immune checkpoint inhibitors","volume":"23","author":"Park","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1111\/ced.15215","article-title":"Cutaneous immune-related adverse events and photodamaged skin in patients with metastatic melanoma: could nicotinamide be useful?","volume":"47","author":"De Giorgi","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jamaoncol.2021.4318","article-title":"Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors: a systematic review","volume":"8","author":"Nadelmann","year":"2022","journal-title":"JAMA Oncol"},{"key":"B16","article-title":"Mucocutaneous toxicities associated with immune checkpoint inhibitors","author":"Patel","year":""},{"key":"B17","doi-asserted-by":"publisher","first-page":"1889449","DOI":"10.1080\/21645515.2021.1889449","article-title":"\u201cSkin rashes\u201d and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management","volume":"18","author":"Sollena","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"898790","DOI":"10.3389\/fmed.2022.898790","article-title":"High grade dermatologic adverse events associated with immune checkpoint blockade for cancer","volume":"9","author":"Kuo","year":"2022","journal-title":"Front Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.clindermatol.2020.06.011","article-title":"Cutaneous immune-related adverse events to checkpoint inhibitors","volume":"38","author":"Malviya","year":"2020","journal-title":"Clin Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.jaad.2022.08.001","article-title":"A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes","volume":"87","author":"Bur","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e25513","DOI":"10.1097\/MD.0000000000025513","article-title":"Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: a case report","volume":"100","author":"Langan","year":"2021","journal-title":"Medicine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1111\/jocd.13914","article-title":"Nivolumab-induced plaque morphea in a malign melanoma patient","volume":"20","author":"Acar","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/ajco.13346","article-title":"Rheumatic immune-related adverse events induced by immune checkpoint inhibitors","volume":"17","author":"Zhong","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"762247","DOI":"10.3389\/fmed.2021.762247","article-title":"Rheumatic manifestations and diseases from immune checkpoint inhibitors in cancer immunotherapy","volume":"8","author":"Shen","year":"2021","journal-title":"Front Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jaad.2021.07.022","article-title":"Treatment recommendations for nail unit toxicities secondary to targeted cancer therapy based on collective experience and evidence-based literature review","volume":"87","author":"Wetzel","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0001","article-title":"Pembrolizumab-induced follicular eruption and response to isotretinoin","author":"O'Connor","year":"2021","journal-title":"Immunotherapy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/dermatopathology8010007","article-title":"Anti-PD-1-induced hidradenitis suppurativa","volume":"8","author":"Maillard","year":"2021","journal-title":"Dermatopathology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S0190","DOI":"10.1016\/j.jaad.2022.08.063","article-title":"Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: a multicenter retrospective study","author":"Freites-Martinez","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"13030\/qt4hs6n388","DOI":"10.5070\/D3274053158","article-title":"Pembrolizumab-associated pyoderma gangrenosum in a patient with metastatic squamous cell carcinoma","volume":"27","author":"Tsibris","year":"2021","journal-title":"Dermatol Online J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/cup.14242","article-title":"Immune cell subsets in interface cutaneous immune-related adverse events associated with anti-PD-1 therapy resemble acute graft versus host disease more than lichen planus","volume":"49","author":"Almodovar Cruz","year":"2022","journal-title":"J Cutan Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1097\/DER.0000000000000670","article-title":"Treatment of checkpoint inhibitor-induced vitiligo in a patient with metastatic renal cell cancer","volume":"32","author":"Karri","year":"2021","journal-title":"Dermatitis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e15432","DOI":"10.1111\/dth.15432","article-title":"Lichen planus pemphigoides: a unique form of bullous and lichenoid eruptions secondary to nivolumab","volume":"35","author":"Shah","year":"2022","journal-title":"Dermatol Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/DAD.0000000000002139","article-title":"Lichen planus pemphigoides associated with PD-1 and PD-L1 inhibitors: a case series and review of the literature","volume":"44","author":"Boyle","year":"2022","journal-title":"Am J Dermatopathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15097","article-title":"A case of severe nivolumab-induced lichen planus pemphigoides in a child with metastatic spitzoid melanoma","author":"Mueller","year":"","journal-title":"Pediatr Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1111\/1346-8138.16006","article-title":"Lichen planus pemphigoides with antibodies against the BP18\u00b0 C-terminal domain induced by pembrolizumab in a melanoma patient","volume":"48","author":"Yoshida","year":"2021","journal-title":"J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jdcr.2022.08.030","article-title":"Pembrolizumab-induced rash in a patient with angiosarcoma","volume":"29","author":"Qian","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/cup.14299","article-title":"Lichen-planus-pemphigoides-like reaction to PD-1 checkpoint blockade","volume":"49","author":"Wat","year":"2022","journal-title":"J Cutan Pathol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"108395","DOI":"10.1016\/j.clim.2020.108395","article-title":"Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations","volume":"214","author":"Gremese","year":"2020","journal-title":"Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"13030\/qt4c21b068","DOI":"10.5070\/D3268049887","article-title":"Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature","volume":"26","author":"Messer","year":"2020","journal-title":"Dermatol Online J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"vii40","DOI":"10.1093\/rheumatology\/kez297","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58","author":"Abdel-Wahab","year":"2019","journal-title":"Rheumatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000525887","article-title":"Scleroderma-like syndrome in the setting of pembrolizumab therapy for non-small cell lung cancer: diagnosis and dermatologic management","volume":"14","author":"Fattore","year":"2022","journal-title":"Case Rep Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jdcr.2022.10.007","article-title":"Durvalumab associated generalized morphea with overlapping vitiligo","volume":"30","author":"Martel","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"102596","DOI":"10.1016\/j.autrev.2020.102596","article-title":"Risk of scleroderma according to the type of immune checkpoint inhibitors","volume":"19","author":"Terrier","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s41927-021-00238-8","article-title":"Small vessel vasculitis and dry gangrene secondary to combined CTLA-4 and PD-1 blockade in malignant mesothelioma","volume":"6","author":"Kefas","year":"2022","journal-title":"BMC Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2147\/CCID.S343876","article-title":"A case of IgA vasculitis during nivolumab therapy for renal cell carcinoma","volume":"14","author":"Nagaoka-Takatori","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12890-020-01375-5","article-title":"Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report","volume":"21","author":"Harada","year":"2021","journal-title":"BMC Pulm Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ejca.2021.05.041","article-title":"Immune checkpoint inhibitor-associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation","volume":"158","author":"Chanson","year":"2021","journal-title":"Eur J Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e14171","DOI":"10.1111\/dth.14171","article-title":"Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: a review","volume":"33","author":"Antoury","year":"2020","journal-title":"Dermatol Ther"},{"key":"B50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.5021\/ad.2021.33.3.284","article-title":"Nivolumab-induced alopecia areata: a case report and literature review","volume":"33","author":"Kim","year":"2021","journal-title":"Ann Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1111\/jocd.13388","article-title":"Eosinophilic folliculitis of the scalp associated with PD-1\/PDL1 inhibitors","volume":"19","author":"Rossi","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e15731","DOI":"10.1097\/MD.0000000000015731","article-title":"Risk of dermatologic and mucosal adverse events associated with PD-1\/PD-L1 inhibitors in cancer patients: a meta-analysis of randomized controlled trials","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e26950","DOI":"10.7759\/cureus.26950","article-title":"Onychopathy induced by nivolumab: a targeted immunotherapy","volume":"14","author":"Zahoor","year":"2022","journal-title":"Cureus"},{"key":"B54","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jdcr.2021.02.016","article-title":"Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: histopathologic description","volume":"10","author":"van Damme","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e494","DOI":"10.4317\/medoral.24353","article-title":"Oral mucositis. Is it present in the immunotherapy of the immune checkpoint PD1\/PD-L1 against oral cancer? A systematic review","volume":"26","author":"Pe\u00f1a-Cardelles","year":"2021","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"B56","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/odi.13218","article-title":"Oral immune-related adverse events associated with PD-1 inhibitor therapy: a case series","volume":"26","author":"Shazib","year":"2020","journal-title":"Oral Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3892\/mco.2022.2512","article-title":"Nivolumab-induced lichenoid granulomatous stomatitis in a patient with advanced melanoma: a case report","volume":"16","author":"Gouveris","year":"2022","journal-title":"Mol Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e21708","DOI":"10.7759\/cureus.21708","article-title":"Pembrolizumab-induced immune-mediated glossitis","volume":"14","author":"Alias","year":"2022","journal-title":"Cureus"},{"key":"B59","year":""},{"key":"B60","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-3-030-41008-7_11","article-title":"Skin reactions to immune checkpoint inhibitors","volume":"1244","author":"Patel","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2023.1147513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T04:24:47Z","timestamp":1677731087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2023.1147513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":61,"alternative-id":["10.3389\/falgy.2023.1147513"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2023.1147513","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"article-number":"1147513"}}